Is PAIN a side effect of SORAFENIB (RAF KINASE INHIBITOR) ? ( FactMed.com )

About this FactMed analysis covering adverse side effect reports of SORAFENIB (RAF KINASE INHIBITOR) patients who developed PAIN.

FactMed provides MD-approved analysis to help both patients, researchers, and physicians accurately assess the risk profile for more than 20,000 different pharmaceutical products. The below report offers compiled information from Food & Drug Administration and FactMed user submissions. Between January 2004 and October 2012, 38 individuals taking SORAFENIB (RAF KINASE INHIBITOR) reported PAIN to the FDA. A total of 3329 SORAFENIB (RAF KINASE INHIBITOR) drug adverse event reaction reports were made with the FDA during this time period. Often the FDA only receives reports of the most critical and severe cases; these numbers may therefore underrepresent the complication rate of the medication.

FDA Research Report

Introduction This page is designed to help you determine the relationship, if any, between SORAFENIB (RAF KINASE INHIBITOR) and PAIN. In doing so, we compare SORAFENIB (RAF KINASE INHIBITOR) with other drugs that cause PAIN, to help you evaluate whether or not SORAFENIB (RAF KINASE INHIBITOR) causes PAIN. Likewise, this page shows the most highly-reported side effects of SORAFENIB (RAF KINASE INHIBITOR), so you can see if PAIN ranks among SORAFENIB (RAF KINASE INHIBITOR)'s most well-known side effects.

Summary Statistics
Reports of SORAFENIB (RAF KINASE INHIBITOR) causing PAIN: 38
Reports of any side effect of SORAFENIB (RAF KINASE INHIBITOR) : 3329
Percentage of SORAFENIB (RAF KINASE INHIBITOR) patients where PAIN is a reported side effect: 1.1415%

FDA reports of any drug causing PAIN : 147781
Average percentage for all medicated patients where PAIN is reported as a complication: 0.9262%

Physician opinion on SORAFENIB (RAF KINASE INHIBITOR) as adverse event culprit:

Overall opinion for all reports of this drug:

Most frequent diagnoses/indications for prescribing SORAFENIB (RAF KINASE INHIBITOR):

HEPATIC NEOPLASM MALIGNANT ( 770 patients )
RENAL CELL CARCINOMA ( 114 patients )
THYROID CANCER ( 65 patients )
METASTATIC RENAL CELL CARCINOMA ( 44 patients )
THYROID CANCER METASTATIC ( 35 patients )
BREAST CANCER ( 31 patients )
BREAST CANCER METASTATIC ( 27 patients )
GASTRIC CANCER ( 25 patients )
NON-SMALL CELL LUNG CANCER ( 25 patients )
COLORECTAL CANCER METASTATIC ( 22 patients )
RENAL CANCER ( 17 patients )
PRODUCT USED FOR UNKNOWN INDICATION ( 14 patients )
BILE DUCT CANCER ( 14 patients )
SALIVARY GLAND CANCER ( 7 patients )
HEPATIC CANCER METASTATIC ( 7 patients )
COLORECTAL CANCER ( 7 patients )
SMALL CELL LUNG CANCER STAGE UNSPECIFIED ( 6 patients )
RECTAL CANCER ( 5 patients )
PANCREATIC CARCINOMA ( 4 patients )
PROSTATE CANCER ( 4 patients )
INTRAOCULAR MELANOMA ( 4 patients )
HEPATIC NEOPLASM MALIGNANT RECURRENT ( 3 patients )
NEOPLASM ( 3 patients )
LIVER DISORDER ( 3 patients )
ANGIOSARCOMA ( 3 patients )
NON-SMALL CELL LUNG CANCER STAGE IV ( 3 patients )
METASTASES TO LUNG ( 3 patients )
HEPATIC NEOPLASM MALIGNANT NON-RESECTABLE ( 3 patients )
COLORECTAL CANCER STAGE IV ( 3 patients )
NEOPLASM MALIGNANT ( 3 patients )
GALLBLADDER CANCER METASTATIC ( 3 patients )
BILIARY CANCER METASTATIC ( 3 patients )
METASTASIS ( 3 patients )
COLON CANCER METASTATIC ( 2 patients )
HYPOPHARYNGEAL CANCER ( 2 patients )
DESMOID TUMOUR ( 2 patients )
NEUROENDOCRINE CARCINOMA ( 2 patients )
ACUTE MYELOID LEUKAEMIA (IN REMISSION) ( 2 patients )
LUNG NEOPLASM MALIGNANT ( 2 patients )
OESOPHAGEAL CARCINOMA ( 2 patients )
METASTATIC MALIGNANT MELANOMA ( 2 patients )
TONGUE NEOPLASM MALIGNANT STAGE UNSPECIFIED ( 2 patients )
METASTATIC SQUAMOUS CELL CARCINOMA ( 2 patients )
ANGINA PECTORIS ( 2 patients )
RENAL CELL CARCINOMA STAGE IV ( 2 patients )
OSTEOSARCOMA METASTATIC ( 2 patients )
BONE SARCOMA ( 2 patients )
METASTATIC OCULAR MELANOMA ( 2 patients )
METASTATIC SALIVARY GLAND CANCER ( 2 patients )
TONSIL CANCER ( 2 patients )
MYELODYSPLASTIC SYNDROME ( 1 patients )
PROSTATE CANCER METASTATIC ( 1 patients )
GALLBLADDER CANCER ( 1 patients )
NEUROENDOCRINE TUMOUR ( 1 patients )
MALIGNANT NEOPLASM OF RENAL PELVIS ( 1 patients )
GLIOMA ( 1 patients )
BLADDER CANCER ( 1 patients )
OVARIAN CANCER METASTATIC ( 1 patients )
CAROTID ARTERY DISEASE ( 1 patients )
HEPATOBLASTOMA ( 1 patients )
NASOPHARYNGEAL CANCER ( 1 patients )
ACUTE MYELOID LEUKAEMIA ( 1 patients )
LUNG ADENOCARCINOMA ( 1 patients )
RENAL CANCER METASTATIC ( 1 patients )
DIFFUSE LARGE B-CELL LYMPHOMA ( 1 patients )
NEUROENDOCRINE CARCINOMA OF THE SKIN ( 1 patients )
MALIGNANT HISTIOCYTOSIS ( 1 patients )
ANTICOAGULANT THERAPY ( 1 patients )
MALIGNANT SOFT TISSUE NEOPLASM ( 1 patients )
SARCOMA ( 1 patients )
GERM CELL CANCER ( 1 patients )
OESOPHAGEAL ADENOCARCINOMA ( 1 patients )
SQUAMOUS CELL CARCINOMA ( 1 patients )
HEAD AND NECK CANCER ( 1 patients )
OVARIAN EPITHELIAL CANCER ( 1 patients )
( 0 patients )

Drugs with high FDA adverse event association with PAIN:

YAZ (18014 patients)
YASMIN (16929 patients)
TRASYLOL (13189 patients)
ZOMETA (11218 patients)
ASPIRIN (9964 patients)
HUMIRA (7884 patients)
FOSAMAX (7692 patients)
LYRICA (7578 patients)
VIOXX (6927 patients)
FORTEO (6503 patients)
LIPITOR (6432 patients)
LASIX (6318 patients)
NEXIUM (6253 patients)
DROSPIRENONE AND ETHINYL ESTRADIOL (6165 patients)
AREDIA (5968 patients)
NEURONTIN (5648 patients)
PREDNISONE (5529 patients)
LISINOPRIL (5394 patients)
MAGNEVIST (5090 patients)
OXYCONTIN (5002 patients)
ENBREL (4826 patients)
COUMADIN (4669 patients)
SYNTHROID (4528 patients)
CELEBREX (4429 patients)
AVONEX (4390 patients)
IBUPROFEN (4227 patients)
METOCLOPRAMIDE (4161 patients)
XANAX (4145 patients)
HEPARIN (4115 patients)
DURAGESIC-100 (4114 patients)
PRILOSEC (4104 patients)
AMBIEN (4017 patients)
DIGOXIN (3947 patients)
TYSABRI (3714 patients)
PROTONIX (3685 patients)
VICODIN (3667 patients)
METHOTREXATE (3628 patients)
ZOLOFT (3623 patients)
ATENOLOL (3587 patients)
CYMBALTA (3581 patients)
PERCOCET (3506 patients)
LEVAQUIN (3428 patients)
OMEPRAZOLE (3409 patients)
PLAVIX (3363 patients)
OMNISCAN (3271 patients)
FOLIC ACID (3266 patients)
VITAMIN D (3228 patients)
NORVASC (3216 patients)
SIMVASTATIN (3212 patients)
HYDROCHLOROTHIAZIDE (3202 patients)
FUROSEMIDE (3202 patients)
ALBUTEROL (3202 patients)
GABAPENTIN (3198 patients)
ZOCOR (3183 patients)
ACETAMINOPHEN (3172 patients)
NITROGLYCERIN (3052 patients)
LEXAPRO (2963 patients)
PREVACID (2885 patients)
TOPROL-XL (2881 patients)
FENTANYL (2860 patients)
SEROQUEL (2845 patients)
ATIVAN (2724 patients)
OXYCODONE HCL (2670 patients)
CALCIUM (2649 patients)
PAXIL (2591 patients)
MORPHINE (2581 patients)
LEVOTHYROXINE SODIUM (2527 patients)
POTASSIUM CHLORIDE (2483 patients)
AVANDIA (2456 patients)
DEXAMETHASONE (2453 patients)
CRESTOR (2444 patients)
LORAZEPAM (2399 patients)
LORTAB (2334 patients)
INSULIN (2316 patients)
METFORMIN HCL (2274 patients)
AMOXICILLIN (2223 patients)
ZOFRAN (2203 patients)
MIRENA (2181 patients)
REMICADE (2172 patients)
ADVAIR DISKUS 100/50 (2170 patients)
SANDOSTATIN LAR (2136 patients)
METOPROLOL TARTRATE (2110 patients)
MULTI-VITAMINS (2107 patients)
EFFEXOR (2078 patients)
PREDNISONE TAB (2055 patients)
PREMARIN (2046 patients)
DIOVAN (2019 patients)
CLONAZEPAM (2019 patients)
DECADRON (2017 patients)
PROZAC (2011 patients)
OPTIMARK (1997 patients)
ACETYLSALICYLIC ACID SRT (1952 patients)
VANCOMYCIN (1925 patients)
HEPARIN SODIUM INJECTION (1908 patients)
COREG (1882 patients)
KLONOPIN (1857 patients)
ALPRAZOLAM (1855 patients)
FLEXERIL (1841 patients)
CELEXA (1833 patients)
ZYRTEC (1825 patients)
SINGULAIR (1824 patients)
WARFARIN SODIUM (1822 patients)
PROTAMINE SULFATE (1818 patients)
ALLOPURINOL (1799 patients)
CHANTIX (1762 patients)
WELLBUTRIN (1741 patients)
DILAUDID (1738 patients)
TRAMADOL HCL (1704 patients)
MULTI-VITAMIN (1703 patients)
LANTUS (1691 patients)
MULTIHANCE (1674 patients)
VALIUM (1661 patients)
ZANTAC (1657 patients)
PROHANCE (1643 patients)
FENTANYL-100 (1611 patients)
VERSED (1593 patients)
LOVENOX (1580 patients)
REGLAN (1576 patients)
CIPROFLOXACIN (1571 patients)
LOPRESSOR (1566 patients)
RED BLOOD CELLS (1548 patients)
MOTRIN (1540 patients)
REBIF (1524 patients)
FEMARA (1518 patients)
BENADRYL (1515 patients)
TRAZODONE HCL (1503 patients)
ASCORBIC ACID (1492 patients)
DIAZEPAM (1483 patients)
ZITHROMAX (1466 patients)
CEPHALEXIN (1457 patients)
MORPHINE SULFATE (1450 patients)
CALCIUM CARBONATE (1448 patients)
CHEMOTHERAPEUTICS NOS (1446 patients)
NAPROXEN (1436 patients)
PROMETHAZINE (1436 patients)
LIDOCAINE (1434 patients)
ARANESP (1412 patients)
CLONIDINE (1392 patients)
RECLAST (1388 patients)
HYDROCODONE (1380 patients)
CLINDAMYCIN (1377 patients)
TAXOTERE (1357 patients)
ARIMIDEX (1356 patients)
EPOGEN (1323 patients)
TAMOXIFEN CITRATE (1311 patients)
THALIDOMIDE (1306 patients)
COLACE (1300 patients)
ALLEGRA (1279 patients)
AMITRIPTYLINE HCL (1271 patients)
REVLIMID (1266 patients)
FISH OIL (1263 patients)
PEPCID (1261 patients)
GLUCOPHAGE (1260 patients)
XELODA (1256 patients)
FLONASE (1253 patients)
COMPAZINE (1250 patients)
SPIRONOLACTONE (1244 patients)
METOPROLOL (1239 patients)
HYDROCODONE BITARTRATE (1232 patients)
VITAMIN B-12 (1230 patients)
OCELLA (1226 patients)
ACTONEL (1222 patients)
BACLOFEN (1219 patients)
TOPAMAX (1204 patients)
AZITHROMYCIN (1195 patients)
AMLODIPINE (1187 patients)
FLUCONAZOLE (1176 patients)
BONIVA (1170 patients)
RADIATION THERAPY (1169 patients)
ZETIA (1161 patients)
COZAAR (1155 patients)
MIRAPEX (1155 patients)
SPIRIVA (1142 patients)
ELAVIL (1140 patients)
ALEVE (CAPLET) (1138 patients)
VITAMIN E (1134 patients)
TYLENOL (CAPLET) (1131 patients)
TYLENOL (1126 patients)
EXJADE (1125 patients)
VELCADE (1123 patients)
FLOMAX (1110 patients)
FERROUS SULFATE TAB (1093 patients)
EFFEXOR XR (1089 patients)
OXYCODONE (1088 patients)
ALTACE (1078 patients)
ACTOS (1077 patients)
GADOLINIUM IN UNSPECIFIED DRUG (1069 patients)
AVELOX (1068 patients)
BETASERON (1064 patients)
AMIODARONE HCL (1063 patients)
CIPRO (1060 patients)
ACCUTANE (1053 patients)
GLIPIZIDE (1052 patients)
BEXTRA (1045 patients)
RANITIDINE (1044 patients)
SOMA (1041 patients)
MIRALAX (1034 patients)
ULTRAM (1029 patients)
MS CONTIN (1025 patients)
DOXYCYCLINE (1005 patients)
TEMAZEPAM (1005 patients)
PLATELETS (1004 patients)
DEPAKOTE (999 patients)
IRON (994 patients)
VALTREX (988 patients)
FLAGYL (983 patients)
ACYCLOVIR (982 patients)
CYTOXAN (978 patients)
HUMALOG (964 patients)
CLARITIN (962 patients)

Most common side effects for patients taking SORAFENIB (RAF KINASE INHIBITOR):

DIARRHOEA (613 patients)
HEPATIC FAILURE (378 patients)
PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME (342 patients)
HEPATIC ENCEPHALOPATHY (320 patients)
FATIGUE (300 patients)
RASH (276 patients)
ASCITES (253 patients)
ABDOMINAL PAIN (237 patients)
DECREASED APPETITE (226 patients)
UPPER GASTROINTESTINAL HAEMORRHAGE (198 patients)
PYREXIA (191 patients)
ASPARTATE AMINOTRANSFERASE INCREASED (179 patients)
NAUSEA (165 patients)
HYPERTENSION (160 patients)
ASTHENIA (154 patients)
DEHYDRATION (140 patients)
HEPATIC FUNCTION ABNORMAL (133 patients)
DYSPNOEA (131 patients)
CONFUSIONAL STATE (131 patients)
HYPOKALAEMIA (125 patients)
ALOPECIA (124 patients)
VOMITING (118 patients)
CONSTIPATION (115 patients)
INTERSTITIAL LUNG DISEASE (114 patients)
LEFT VENTRICULAR DYSFUNCTION (113 patients)
DEATH (113 patients)
ENDOCARDITIS (112 patients)
ARTHRALGIA (111 patients)
STOMATITIS (111 patients)
ABDOMINAL PAIN UPPER (110 patients)
JAUNDICE (108 patients)
HEPATIC NEOPLASM MALIGNANT (106 patients)
GASTROINTESTINAL HAEMORRHAGE (106 patients)
RETINAL VASCULAR THROMBOSIS (103 patients)
LOWER GASTROINTESTINAL HAEMORRHAGE (103 patients)
LIVER CARCINOMA RUPTURED (101 patients)
OEDEMA PERIPHERAL (97 patients)
PLEURAL EFFUSION (97 patients)
STAPHYLOCOCCAL INFECTION (96 patients)
PNEUMONIA BACTERIAL (96 patients)
ENTEROBACTER INFECTION (96 patients)
MYOPATHY (95 patients)
DRY MOUTH (94 patients)
PAIN IN EXTREMITY (93 patients)
ANXIETY (90 patients)
MALAISE (89 patients)
PULMONARY EMBOLISM (85 patients)
ANAEMIA (84 patients)
PLATELET COUNT DECREASED (81 patients)
BACK PAIN (79 patients)
SEPSIS (78 patients)
PRURITUS (78 patients)
DUODENAL ULCER (77 patients)
MIGRAINE (76 patients)
MITRAL VALVE INCOMPETENCE (76 patients)
HYPOGLYCAEMIA (76 patients)
C-REACTIVE PROTEIN INCREASED (74 patients)
BLOOD PRESSURE INCREASED (73 patients)
VARICES OESOPHAGEAL (73 patients)
HEADACHE (72 patients)
RETINAL VEIN OCCLUSION (72 patients)
ABASIA (69 patients)
RENAL FAILURE ACUTE (69 patients)
WEIGHT DECREASED (67 patients)
DEEP VEIN THROMBOSIS (67 patients)
DIZZINESS (65 patients)
ERYTHEMA (65 patients)
GENERAL PHYSICAL HEALTH DETERIORATION (64 patients)
CONVULSION (63 patients)
ALANINE AMINOTRANSFERASE INCREASED (62 patients)
DYSPHONIA (62 patients)
CEREBRAL HAEMORRHAGE (60 patients)
APHAGIA (58 patients)
COLITIS (58 patients)
PNEUMONIA (57 patients)
GASTRIC ULCER (56 patients)
HYPONATRAEMIA (55 patients)
HAEMOGLOBIN DECREASED (53 patients)
RESPIRATORY FAILURE (52 patients)
LUNG DISORDER (52 patients)
CEREBRAL ISCHAEMIA (49 patients)
PARAESTHESIA (49 patients)
BLOOD BILIRUBIN INCREASED (48 patients)
GAIT DISTURBANCE (48 patients)
THYROID CANCER METASTATIC (44 patients)
DEPRESSED LEVEL OF CONSCIOUSNESS (43 patients)
PERICARDIAL EFFUSION (41 patients)
THROMBOCYTOPENIA (41 patients)
BLISTER (41 patients)
FEBRILE NEUTROPENIA (40 patients)
BLOOD LACTATE DEHYDROGENASE INCREASED (40 patients)
HALLUCINATION (40 patients)
CHILLS (40 patients)
AMMONIA INCREASED (39 patients)
SKIN ULCER (39 patients)
BLOOD ALKALINE PHOSPHATASE INCREASED (38 patients)
PAIN (38 patients)
HYPOALBUMINAEMIA (38 patients)
HYPOCALCAEMIA (37 patients)
FALL (37 patients)
POLLAKIURIA (37 patients)
BLOOD PRESSURE DECREASED (37 patients)
SKIN EXFOLIATION (37 patients)
INSOMNIA (36 patients)
CARDIAC ARREST (36 patients)
HYPOAESTHESIA (35 patients)
INFECTIOUS PERITONITIS (35 patients)
MYOCARDIAL INFARCTION (35 patients)
RETINAL VASCULAR DISORDER (34 patients)
RENAL FAILURE (34 patients)
LIPASE INCREASED (34 patients)
HYPERKALAEMIA (33 patients)
HYPERGLYCAEMIA (33 patients)
HAEMOPTYSIS (31 patients)
ATRIAL FIBRILLATION (30 patients)
GENERALISED OEDEMA (30 patients)
FAECAL INCONTINENCE (30 patients)
WHITE BLOOD CELL COUNT DECREASED (30 patients)
CELLULITIS (29 patients)
CHEST PAIN (29 patients)
SOMNOLENCE (29 patients)
HYPERBILIRUBINAEMIA (28 patients)
HYPOTENSION (28 patients)
MUSCLE SPASMS (28 patients)
ABDOMINAL DISTENSION (27 patients)
WHITE BLOOD CELL COUNT INCREASED (27 patients)
VISION BLURRED (27 patients)
HEPATIC PAIN (26 patients)
BLOOD ALBUMIN DECREASED (26 patients)
DYSURIA (25 patients)
RASH GENERALISED (25 patients)
BLOOD SODIUM DECREASED (25 patients)
BLOOD URIC ACID INCREASED (25 patients)
COMA (25 patients)
COUGH (25 patients)
PANCYTOPENIA (25 patients)
ACUTE ABDOMEN (24 patients)
EOSINOPHIL COUNT INCREASED (24 patients)
CEREBROVASCULAR ACCIDENT (24 patients)
METASTASES TO CENTRAL NERVOUS SYSTEM (23 patients)
CEREBRAL INFARCTION (23 patients)
HYPOMAGNESAEMIA (23 patients)
RETINAL VEIN THROMBOSIS (23 patients)
GAMMA-GLUTAMYLTRANSFERASE INCREASED (23 patients)
TUMOUR LYSIS SYNDROME (22 patients)
HYPOPHOSPHATAEMIA (22 patients)
INFECTION (22 patients)
ORAL PAIN (22 patients)
BLOOD CREATININE INCREASED (22 patients)
NEUTROPENIA (22 patients)
RENAL IMPAIRMENT (22 patients)
LETHARGY (22 patients)
SKIN TOXICITY (21 patients)
TONGUE BLISTERING (21 patients)
LIVER ABSCESS (21 patients)
HAEMATEMESIS (21 patients)
OESOPHAGEAL VARICES HAEMORRHAGE (20 patients)
MENTAL IMPAIRMENT (20 patients)
NERVOUSNESS (20 patients)
NEPHROTIC SYNDROME (20 patients)
HYPOPHAGIA (20 patients)
ADRENAL INSUFFICIENCY (19 patients)
DRY SKIN (19 patients)
BLOOD AMYLASE INCREASED (19 patients)
OEDEMA (19 patients)
INFECTIOUS PLEURAL EFFUSION (19 patients)
DYSPEPSIA (19 patients)
COMA HEPATIC (19 patients)
HEART RATE INCREASED (18 patients)
HYPERTENSIVE CRISIS (18 patients)
MYALGIA (18 patients)
ECZEMA (18 patients)
URINARY TRACT INFECTION (18 patients)
NEUROMYOPATHY (18 patients)
MEDICAL DEVICE COMPLICATION (18 patients)
DIVERTICULITIS (18 patients)
OSTEOMYELITIS (18 patients)
CEREBRAL ATROPHY (18 patients)
CEREBRAL VENTRICLE DILATATION (18 patients)
DIABETIC FOOT INFECTION (18 patients)
NECK PAIN (18 patients)
OLIGURIA (17 patients)
GASTROINTESTINAL DISORDER (17 patients)
HAEMATOCHEZIA (17 patients)
DISSEMINATED INTRAVASCULAR COAGULATION (17 patients)
HYPOTHYROIDISM (17 patients)
TRANSAMINASES INCREASED (17 patients)
OROPHARYNGEAL PAIN (17 patients)
CHRONIC MYELOID LEUKAEMIA (17 patients)
NEOPLASM PROGRESSION (17 patients)
METASTASES TO ADRENALS (16 patients)
LYMPHOCYTE COUNT DECREASED (16 patients)
INTERNATIONAL NORMALISED RATIO INCREASED (16 patients)
MULTI-ORGAN FAILURE (16 patients)
FEAR (16 patients)
PANCREATIC CARCINOMA (16 patients)
HYPERSOMNIA (16 patients)
EPILEPSY (16 patients)
SUBARACHNOID HAEMORRHAGE (16 patients)
METASTASES TO LUNG (16 patients)
TACHYCARDIA (16 patients)
MUSCULAR WEAKNESS (16 patients)
KLEBSIELLA SEPSIS (16 patients)
MYOCARDIAL ISCHAEMIA (16 patients)
DYSGEUSIA (16 patients)
LUNG INFECTION (16 patients)
FAECES DISCOLOURED (16 patients)
PAIN OF SKIN (16 patients)
SPINAL FRACTURE (16 patients)
PANIC REACTION (16 patients)

In addition to reviewing our up-to-date FDA research, users may interact with the FactMed community - currently one million members and growing! FactMed online research and discussions are read by patients, scientists, physicians, and other interested health care parties. Post follow up Questions to learn from our diverse readership. Likewise, patients who have experienced unwanted effects are encouraged to share their Concerns to help educate and inform our members.

Recent FactMed Activity for SORAFENIB (RAF KINASE INHIBITOR)

Issue	Description / Topic	Timestamp

My Patient Resources

Get your questions answered! Over one million patients, researchers, and health care providers have visited FactMed. If you have a question about PAIN and SORAFENIB (RAF KINASE INHIBITOR), post it here. You may receive a response from a fellow patient - or a leading expert in the field.

Your Question:

Share your experience: Over one million patients, researchers, and health care providers have visited FactMed. If you have a noteworthy experience as a patient taking SORAFENIB (RAF KINASE INHIBITOR), post it here. Your story could help a fellow patient - or provide insight to a leading expert in the field.

Your Experience or Concern:

Telemedicine Expert Consults FactMed newest feature allows patients to consult - via realtime videoconferencing - experts in SORAFENIB (RAF KINASE INHIBITOR). This premium feature connects patients to experts, regardless of geography. FactMed experts charge reasonable rates that may be reimbursable by your insurance as a second-opinion.

We are currently accepting registration for SORAFENIB (RAF KINASE INHIBITOR) experts. If you are a healthcare provider experienced in prescribing SORAFENIB (RAF KINASE INHIBITOR), please register here.